AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$TEVA

Teva ADR earnings beat by $0.14, revenue topped estimates

Teva Pharmaceutical (TEVA) reported Q3 EPS of $0.86, beating estimates by $0.14, with revenue of $4.4B, exceeding expectations of $4.25B. The stock is up 15.1% in 3 months and 98.92% in 12 months. InvestingPro rates its financial health as 'good performance.'

Original reporting
investing.com
Published Nov 3, 2026, 12:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TEVA
Bullish
high confidence
Mentioned
$TEVA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The beat could trigger short‑term buying pressure, especially in after‑hours trading, and may improve sentiment toward the pharma sector.

02

Market read

Earnings beat provides a fresh catalyst for TEVA and may influence related pharma stocks.

03

What to watch

Potential headwinds from generic competition not discussed.

Relevance 8/10Novelty 8/10Timing: after-market today

Background

Teva Pharmaceutical Industries reported its third‑quarter results, beating consensus estimates on both earnings and revenue.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Q3 EPS of $0.86 beat estimate by $0.14 and revenue of $4.4B topped consensus of $4.25B.

Expected impact

likely upward pressure as investors price in the earnings beat

Evidence & confidence

Both earnings per share and revenue exceeded expectations, a clear catalyst for short-term buying.

Market effects

Sector

May lift sentiment for the broader pharmaceutical sector.

Regional

Positive for US-listed pharma stocks.

Global

Limited to investors tracking earnings season.

Counterpoint

What could challenge this read

If guidance is weak, the beat may be priced out quickly.

Key entities

  • company
    Teva ADR

    Pharmaceutical manufacturer listed on NYSE as TEVA.

Read at source← All news

StoryTeva reports Q3 2026 results, raises full‑year outlook and announces FDA approval for WELTRUZA

Also covered by

6 outlets

Related articles

NOV 3
$TEVAHighAI 9/10

Teva Q3 2026 slides: biopharma shift lifts margins to 58.7%

Teva Pharmaceuticals (NYSE:TEVA) reported Q3 2026 revenues of $4.4B and adjusted EPS of $0.86, beating estimates. Gross margin rose to 58.7% due to a shift toward biopharma. Key products like AUSTEDO, UZEDY, and AJOVY drove growth. The company raised full-year guidance and announced FDA approval for WELTRUZA, a new schizophrenia treatment.

investing.com3 min
NOV 3
$TEVAMed

Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars

Teva Pharmaceuticals and Samsung Bioepis agreed to license and commercialize two FDA-approved biosimilars in the U.S. Teva will handle sales, with Samsung retaining manufacturing. The deal includes upfront payments, milestones, and profit sharing. Closing is expected by the end of 2026, with rights to etanercept-ykro transferring at that time and infliximab-abda in Q3 2027.

pharmexec.com3 min
NOV 3
$TEVAHighAI 9/10

Teva again raises guidance as branded drugs lift revenue

Teva Pharmaceutical (TEVA) reported Q3 revenue of $4.4B, beating estimates. It raised 2026 revenue guidance to $16.7-$17B. Branded drugs grew 33%, with Austedo, Ajovy, and Uzedy driving sales. GAAP net profit was $233M, while non-GAAP was $1B. Debt refinancing extended maturity to 6.3 years. CEO highlighted FDA approvals and biosimilars agreement with Samsung Bioepis.

en.globes.co.il5 min
NOV 3
$QUREMed

UniQure gets an FDA decision date; Teva scraps brain drug study

UniQure's Huntington's disease gene therapy application is under FDA review with a decision expected by May 1. Teva Pharmaceuticals halted a mid-stage study of emrusolmin for multiple system atrophy due to futility. Bright Minds Biosciences' antiseizure drug trial was partially halted by the FDA. Specific Biologics raised $35M in Series A funding for ALS therapy trials. CinRx Pharma and Graviton BioScience formed a joint venture to develop cardiovascular drugs.

finance.yahoo.com6 min
NOV 3
$TEVAHighAI 8/10

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA): Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial…

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION

SEC EDGAR 8-K2 min